Head-to-head · Cost-Efficiency Index
Human+ vs Näky
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Human+
Cost-first shoppers who want pharmacy-wholesale pricing via a flat membership, in any state.
Visit Human+Näky
Shoppers who want a distinct oral semaglutide drops product and a separate GLP-1 microdose option.
Visit NäkyThe verdict
Human+ and Näky tie on the Cost-Efficiency Index at 58/100, so neither wins outright on the numbers. For most shoppers we'd start with Human+ (ranked #287, a hair above #290) — Cost-first shoppers who want pharmacy-wholesale pricing via a flat membership, in any state. But Näky is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Human+.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Human+ | Näky |
|---|---|---|
| Cost-Efficiency Index | 58/100 | 58/100 |
| Semaglutide / mo | Not disclosed | $145/mo (compounded) |
| Tirzepatide / mo | Not disclosed | $265/mo (compounded) |
| Semaglutide / yr (modeled) | — | $1,740 |
| Tirzepatide / yr (modeled) | — | $3,180 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #287 | #290 |
Human+
58/100Where the value is
- Cost-transparent model: a flat monthly membership with prescriptions billed at pharmacy-wholesale cost instead of marked up
- Available via telehealth in all 50 states
- Filled by US 503A compounding pharmacies and reviewed by board-certified US-licensed clinicians
The tradeoffs
- Specific GLP-1 medications and pricing are not published — you only see them after starting the intake
- Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
Näky
58/100Where the value is
- Distinct oral semaglutide drops product line ($145) as an alternative to injections — uncommon among compounded GLP-1 brands
- Separate GLP-1 microdose program offered ($185) for patients who want a lower-dose protocol
- LegitScript verification is displayed and checkable for the benaky.com domain
The tradeoffs
- No pricing is shown on any customer-facing marketing page — every page checked (homepage, /pricing, /shop, /tirzepatide, /oral-semaglutide, /weight-loss, /pages/faq) either 404'd or omitted dollar figures; prices had to be pulled from a developer-facing JSON feed, not something a typical visitor would find
- A 'Wegovy® Pill' SKU at $149 borrows Novo Nordisk's registered brand name for what does not appear to be an FDA-approved oral Wegovy product — this needs independent verification before being treated as genuine branded access
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.